Personalis Shares Are Trading Higher After the Company and Moderna Recently Announced a Multi-year Extension to Continue Utilizing the Personalis ImmunoID NeXT Platform and Technology for V940/mRNA-4157. The Company Also Announced an Investment From...
Personalis Shares Are Trading Higher After the Company and Moderna Recently Announced a Multi-year Extension to Continue Utilizing the Personalis ImmunoID NeXT Platform and Technology for V940/mRNA-4157. The Company Also Announced an Investment From...
Personalis的股票在公司與Moderna最近宣佈繼續使用Personalis ImmunoID NeXt平台和科技用於V940/mRNA-4157的多年擴展後開始上漲。公司還宣佈了一項投資來自...